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Abstract
Understanding the molecular underpinnings of chemoresistance is vital to design therapies to restore chemosensitivity. In
particular, metadherin (MTDH) has been demonstrated to have a critical role in chemoresistance. Over-expression of MTDH
correlates with poor clinical outcome in breast cancer, neuroblastoma, hepatocellular carcinoma and prostate cancer. MTDH
is also highly expressed in advanced endometrial cancers, a disease for which new therapies are urgently needed. In this
present study, we focused on the therapeutic benefit of MTDH depletion in endometrial cancer cells to restore sensitivity to
cell death. Cells were treated with a combination of tumor necrosis factor-a-related apoptosis-inducing ligand (TRAIL),
which promotes death of malignant cells of the human reproductive tract, and histone deacetylase (HDAC) inhibitors, which
have been shown to increase the sensitivity of cancer cells to TRAIL-induced apoptosis. Our data indicate that depletion of
MTDH in endometrial cancer cells resulted in sensitization of cells that were previously resistant in response to
combinatorial treatment with TRAIL and the HDAC inhibitor LBH589. MTDH knockdown reduced the proportion of cells in S
and increased cell arrest in G2/M in cells treated with LBH589 alone or LBH589 in combination with TRAIL, suggesting that
MTDH functions at the cell cycle checkpoint to accomplish resistance. Using microarray technology, we identified 57
downstream target genes of MTDH, including calbindin 1 and galectin-1, which may contribute to MTDH-mediated
therapeutic resistance. On the other hand, in MTDH depleted cells, inhibition of PDK1 and AKT phosphorylation along with
increased Bim expression and XIAP degradation correlated with enhanced sensitivity to cell death in response to TRAIL and
LBH589. These findings indicate that targeting or depleting MTDH is a potentially novel avenue for reversing therapeutic
resistance in patients with endometrial cancer.
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Introduction
A common problem with cancer therapy is the development of
resistance, and an improved understanding of the underlying
pathways involved with drug resistance could lead to the
development of new strategies to overcome this resistance. A
recently discovered gene, metadherin (MTDH, also known as
AEG-1 or LYRIC) has emerged as a potentially crucial mediator
of tumor progression, metastasis, and resistance to chemotherapies
[1,2,3,4]. MTDH is proposed to promote tumor progression
through the integration of multiple signaling pathways including
ras, myc, Wnt, PI3K/AKT, and NF-kB in various types of cancer
cells [4,5,6,7], though the mechanism by which MTDH controls
these signaling events is unclear. In this study, we investigated the
role of MTDH in endometrial cancer and its inhibition as a
mechanism to overcome drug resistance.
Initial interest in MTDH as a factor in chemoresistance arose as
a consequence of NCI60 pharmacogenomic data, which found
that the genomic copy number gain on 8q22 is a defining event in
chemoresistance [8]. An earlier study reported that lymph node
metastasis is significantly associated with copy number gains at
8q22–q23 in endometrial cancers [9]. Thus far, MTDH is the only
known gene on 8q22 that has been shown to correlate with poor
clinical outcomes in patients with solid tumors [8]. In vitro and in
vivo chemoresistance analyses confirmed that MTDH knockdown
sensitizes various types of tumors — including breast cancer,
hepatocellular carcinoma, prostate cancer, and neuroblastoma—
to multiple chemotherapy agents such as 5-fluorouracil (5-FU),
cisplatin, paclitaxel, and doxorubicin [1,10,11]. However, the
ability of MTDH knockdown to sensitize cells to targeted
therapies, which have come to symbolize the future of cancer
therapeutics, has not yet been explored.
Tumor necrosis factor (TNF)-a-related apoptosis-inducing
ligand (TRAIL) recently emerged as a promising targeted
therapeutic strategy in various types of cancers due to its pro-
apoptotic characteristics [12,13]. As a member of the TNF family,
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cancer cells by binding to death receptors. Importantly, TRAIL
selectively promotes apoptosis of tumor cells but has no effect on
normal human reproductive tract cells including those in the
endometrium, ovary, cervix, or fallopian tube [13]. Some cancer
cells are resistant to TRAIL-induced apoptosis [14,15,16],
therefore combinatorial regimens have been adopted to restore
sensitivity [13,17]. In several studies, histone deacetylase (HDAC)
inhibitors have been demonstrated to further increase sensitivity to
TRAIL-induced apoptotic cell death [18,19,20,21]. Unfortunately
some cancer cells remain resistant to combined TRAIL and
HDAC inhibitor treatment [22], and new approaches to restore
sensitivity to these targeted therapies are necessary.
We examined the effect of depleting MTDH levels on restoring
sensitivity to TRAIL-based targeted therapies. The data reported
herein demonstrate that MTDH regulates cell cycle and cell
survival in response to treatment with HDAC inhibitors and
TRAIL, suggesting that MTDH is a promising therapeutic target
to increase the efficacy of TRAIL and HDAC inhibitor
combinatorial treatment.
Results
MTDH expression is elevated in endometrial cancer cell
lines and tissues
MTDH was highly expressed at the protein level in all six
endometrial cancer cell lines tested (RL95, AN3CA, KLE,
Ishikawa, Hec50co and ECC1, Figure 1A). In endometrial cancer
patient tissues, MTDH expression was elevated compared to
normal endometrium (Figure 1B). Specifically, the expression of
80 kDa MTDH and putative 50–55 kDa MTDH isoforms were
significantly higher in endometrial cancer samples including
papillary serous, sarcoma, and adenocarcinoma, whereas MTDH
was undetectable in normal endometrial tissues (Figure 1B).
Because no MTDH was detected in normal endometrial tissue, we
blotted for the tumor suppressor LKB1 as a control (Figure 1B).
Increased expression of cytoplasmic MTDH in endometrial
adenocarcinoma and nuclear MTDH in some metastatic endo-
metrial cancer was also observed in endometrial cancer tissues as
shown in Figure 1C by immunohistochemistry with an MTDH-
specific antibody. XIAP and FLIP are two pro-survival proteins
associated with the death receptor-induced extrinsic apoptotic
pathway [12]. We therefore examined whether there is a
correlation between expression of pro-survival proteins XIAP
and FLIP with MTDH expression. While expression of MTDH
and XIAP did not correlate, we did detect a correlation with FLIP
expression (Figure 1B). The increased expression of MTDH in all
cancerous cells and tissues examined suggests that it may play a
role in endometrial carcinogenesis.
Knockdown of MTDH reduces colony formation
Due to the elevated expression of MTDH in the various
endometrial cancer cell lines and human endometrial cancer
samples, we next examined the tumorigenic potential of MTDH in
the Type II endometrial cancer cell line Hec50co using a short-
hairpin RNA (shRNA) specific for MTDH. A 3.49-fold reduction
in MTDH gene expression was detected by quantitative real-time
PCR (qRT-PCR) in MTDH shRNA-transfected Hec50co cells
compared to control scrambled shRNA-transfected cells (Table
S1). Depletion of MTDH decreased colony formation in cells
stably expressing MTDH shRNA compared to control shRNA
(Figure 2A, B). These results were confirmed using three shRNA
constructs targeting different regions of MTDH. A similar
phenotype was also observed upon knockdown of MTDH in
Ishikawa H Type I endometrial cancer cells, indicating that
elevated MTDH expression is generally required for endometrial
cancer colony formation.
Identification of MTDH-regulated genes in endometrial
cancer cell lines
To identify downstream genes mediating the tumorigenic effects
of MTDH in endometrial cancer cell lines, an Affymetrix
oligonucleotide microarray (Human gene array 1.0 ST) was used
to detect differentially expressed genes in Hec50co cells stably
transfected with either MTDH shRNA or a control shRNA (Data
have been deposited on GEO, GSE26134). Depletion of MTDH
by knockdown resulted in at least two-fold gene expression
alteration of 57 genes (Figure 3A). Several of these genes were
randomly chosen to confirm the changes by qRT-PCR (Figure 3B).
Data from the array indicated that MTDH regulates expression
of genes involved in invasion, tight junctions, as well as
chemoresistance (Table S1 and S2). For example, galectin-1
(LGALS1) and calbindin 1 (Calb1) were markedly down-regulated
at the mRNA (Figure 3B) and protein levels (Figure 3C) in MTDH
shRNA-transfected Hec50co cells. Calb1 and galectin-1 are two
putative MTDH downstream genes that may regulate the
metabolism of phosphatidylinositol, which is part of the PI3K/
AKT signaling pathway commonly upregulated in endometrial
cancer [23]. We also examined the changes in gene expression in
Ishikawa H endometrial cancer cells in response to MTDH
silencing and observed some overlap with genes that were altered
in Hec50co cells (Table S3 and S4).
We next sought to understand how MTDH regulates the PI3K/
Akt pathway. Expression of galectin-1 is upregulated in various
types of tumors and is reported to mediate tumor invasion and
metastasis by increasing expression of matrix metalloproteinase
MMP-9 and MMP-2 and promoting reorganization of the actin
cytoskeleton [24]. Consistent with a previous study in which
overexpression of MTDH promotes activation of the PI3K/AKT
pathway in neuroblastoma [7], we detected an inhibition of
components of PI3K/AKT signaling pathway in Hec50co cells
with depleted MTDH as compared to control (Figure 3C).
Specifically, a dramatic reduction in PDK1 phosphorylation at
S241 and AKT phosphorylation at both T308 and S473 occurred
in MTDH knockdown cells, although no significant change of
total PDK1 protein level was detected (Figure 3C). Furthermore,
as shown in Figure 3D and E, a dramatic reduction in the level of
PIP3 was detected in Hec50co cells with MTDH shRNA as
compared to cells with control shRNA. These findings demon-
strate that MTDH can activate the pro-survival pathways of
PI3K/AKT via up-regulation of PIP3.
MTDH knockdown sensitizes cells to targeted cancer
therapies
To overcome resistance to therapies, HDAC inhibitors such as
LBH589 have been used to restore TRAIL-induced apoptosis in
various types of cancers [18,19]. Hec50co cells were previously
shown to be resistant to TRAIL-mediated apoptosis [13].
Therefore, to test the influence of MTDH on sensitivity to
TRAIL in these cells, we treated Hec50co cells with or without
MTDH (control vs. MTDH knockdown) with combined TRAIL
and LBH589 treatment for three days and then examined cell
viability. Compared with scrambled shRNA transfected Hec50co
cells, stable MTDH knockdown modestly increased the sensitivity
of Hec50co cells to single agent therapy (either LBH589 or
TRAIL alone, Figure 4A, B). However, as shown in Figure 4B, a
more dramatic induction of sensitivity occurred in stable MTDH
Cell Death Sensitization by MTDH Knockdown
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TRAIL. These data suggest that MTDH expression is an
important factor underlying resistance to the combined regimen.
Apoptosis regulators involved in MTDH-mediated cell
death
To study the molecular mechanism of cell death in MTDH
knockdown cells, expression of proteins associated with apoptosis
(both pro- and anti-apoptotic factors) were tested in MTDH
control and knockdown cells after single treatment (LBH589 or
TRAIL) or after combined treatment (LBH589 and TRAIL). The
combination treatment did not enhance expression of the TRAIL
receptors DR4 and DR5. Additionally, there were no changes in
expression of anti-apoptotic genes Bcl-xL, Mcl-1, or FLIP in
MTDH control and knockdown Hec50co cells after the
combinatorial treatment (Figure 5).
Interestingly, the pro-apoptotic BH3-only protein Bim was up-
regulated in untreated MTDH knockdown Hec50co cells
compared to control cells (Figure 5), which indicates that depletion
of MTDH alone may lead to induction of pro-apoptotic factors.
When control Hec50co cells were treated with LBH589 alone or
in combination with TRAIL, expression of Bim increased. In
contrast, expression of Bim was significantly enhanced in MTDH
knockdown Hec50co cells without any treatment, while treatment
with either LBH589 or TRAIL further enhanced the expression of
Bim. However, Bim expression was slightly decreased in MTDH
knockdown cells after co-treatment with LBH589 and TRAIL.
In control cells, post-translational modification of XIAP
occurred upon treatment with LBH589, as demonstrated by a
higher migrating species, and reduction of both total and modified
XIAP was only detected with LBH589 and TRAIL combination
treatment (Figure 5). This effect was accentuated when MTDH
was knocked down, such that we detected a greater reduction in
XIAP post-translational modification in MTDH knockdown
Hec50co cells compared to control cells after LBH589 and
TRAIL treatment. Furthermore, significant induction of cleavage
of caspase-8, caspase-3 and PARP-1 was detected after single
treatment with LBH589 or TRAIL, or the combination in MTDH
knockdown Hec50co cells compared with control cells. Reduction
of Bid was also observed in MTDH knockdown cells treated with
Figure 1. Overexpression of MTDH was detected in endometrial cancer cell lines and tissues. (A) Expression of MTDH was detected in all
of the six tested endometrial cancer cell lines: RL95, AN3CA, ECC1, Ishikawa H (Ishi), KLE and Hec50 cells. (B) Expression of MTDH was detected in
endometrial tissues from two normal individuals, four patients with papillary serous, three patients with adenocarcinoma, and two patients with
endometrial sarcoma. Expression of the tumor suppressor gene LKB1 and two anti-apoptotic genes, XIAP and FLIP, was also detected by Western
blotting in the same samples. (C) MTDH expression was detected by immunohistochemistry staining using the disease spectrum (endometrial cancer
progression) tissue array with over 50 samples of endometrial tissues from benign to cancer. (i) normal endometrial tissue, (ii) low grade endometrial
adenocarcinoma, (iii) high grade endometrial adenocarcinoma, and (iv) endometrial cancer metastatic to the abdominal cavity. Original
magnification, 6400.
doi:10.1371/journal.pone.0020920.g001
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demonstrate that knockdown of MTDH can increase extrinsic
apoptosis induced by TRAIL and LBH589, and the principal
mechanism is via up-regulation of Bim. Down-regulation of XIAP
and subsequent activation of caspase-8 and caspase-3 as well as
downstream substrates such as PARP-1 also occurs.
Cell cycle checkpoint regulation by MTDH
In order to determine the precise mechanism by which MTDH
confers resistance to TRAIL and LBH589 treatment, we next
investigated the role of MTDH in cell cycle control. Control and
MTDH knockdown Hec50co cells that were untreated or treated
with TRAIL alone had similar cell cycle profiles (Figure 6A). In
contrast, treatment with the HDAC inhibitor LBH589 in cells
lacking MTDH resulted in a greater proportion of cells persistently
in the G2/M phase. When Hec50co MTDH knockdown cells
were treated with both LBH589 and TRAIL, a decreased
proportion of cells were in S phase and an increased proportion
of cells were arrested in G2/M (Fig. 6A). These data show that
MTDH has a significant role in regulating the cell cycle
checkpoint in the context of combinatorial TRAIL and HDAC
inhibitor treatment.
To investigate the mechanism by which MTDH regulates the
cell cycle, expression of cell cycle regulators was measured.
Increase of Aurora A at the protein level was observed in MTDH
knockdown cells as compared to control cells (Figure 6B). When
control and MTDH knockdown Hec50co cells were exposed to
LBH589, there was an increase in Aurora A, Aurora B, acetylation
of histone H3 at lysine 9, phosphorylation of histone H3 at serine
10, and p53-independent up-regulation of p21 WAF1, the
inhibitor of cyclin-dependent kinases (Figure 6B). Interestingly,
TRAIL treatment resulted in a substantial decrease in histone H3
phosphorylation, which corresponded to a decrease in the
percentage of cells in G2/M phase as compared to untreated
cells. Overall these data implicate a novel role for MTDH in
regulating cell cycle checkpoints.
Figure 2. MTDH knockdown inhibits Hec50co colony formation. Hec50co cells were transfected with control or MTDH shRNA expression
vectors. (A) Colonies formed by control or MTDH shRNA-transfected Hec50co cells are shown after the transfection of shRNAs and after selection with
2 ug/ml puromycin for 3 weeks. (B) Quantification of the relative colony formation in control versus MTDH knockdown Hec50co cells.
doi:10.1371/journal.pone.0020920.g002
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Although MTDH has been linked to both metastasis and
resistance to chemotherapy in various types of cancers [1,25], the
mechanism and biological function of MTDH is largely unknown.
Depletion of MTDH can enhance the effects of chemotherapeutic
drugs such as doxorubicin, paclitaxel and 5-FU [10,11]. Here we
report that expression of MTDH is highly elevated in endometrial
cancers tissues compared to normal endometrium. Our data
demonstrate that depletion of MTDH with a specific shRNA can
also increase cellular sensitivity to targeted therapies, including the
HDAC inhibitor LBH589, TRAIL and a combination regimen
with both agents. As depicted in Figure 6C, we have identified the
potential mechanism by which knockdown of MTDH increases
cell death in response to treatment with TRAIL and the HDAC
inhibitor LBH589. Specifically, cells lacking MTDH have
decreased phosphorylation of PDK1 and its substrate AKT,
which in turn stimulates expression of the proapoptotic protein
Bim. Combined LBH589 and TRAIL treatment results in
downregulation of XIAP, thereby allowing activation of caspase-
3 and -8. These molecular changes result in apoptotic cell death in
cells lacking MTDH. Our data suggest therefore that MTDH-
mediated resistance occurs through activation of pro-survival
signaling pathways and potentially by aberrant regulation of cell
cycle checkpoints.
Using a microarray approach, we identified many candidate
genes that are differentially regulated in cells lacking (MTDH
shRNA) or expressing (control shRNA) MTDH. Of particular
interest were calbindin 1(CALB1) and galectin-1, two proteins
that have previously been linked to pro-survival signaling
pathways. CALB1 is a calcium binding protein with four active
calcium binding domains. CALB1 was reported to interact with
Myo-inositol monophosphatase (IMPA) using phage display and
to induce IMPA activity up to 250-fold [26,27]. IMPA is an
Figure 3. MTDH knockdown causes alterations in gene expression and PI3K/AKT signal transduction in Hec50co cells. (A) Heat map
of two-fold change of gene expression (as determined from Affymetrix array data) between control and MTDH knockdown Hec50co cells. (B) Gene
expression changes were validated by qRT-PCR for the indicated genes identified in the microarray (* p,0.05). (C) Expression and/or phosphorylation
of the indicated proteins were examined in Hec50co cells stably expressing either control shRNA or MTDH shRNA. Total PDK1 and b-actin were used
as loading controls. (D,E) Expression of PIP3 was detected in control (D) or MTDH knockdown (E) Hec50co cells by PIP3 immuno-fluorescent staining.
doi:10.1371/journal.pone.0020920.g003
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myo-inositol-1,3-diphosphate, and myo-inositol-1,4-diphosphate
to generate free myo-inositol which plays important role in
programmed cell death [28]. Galectin-1, a beta-galactosidase
binding protein, is strongly expressed in a variety of human
cancers and has been shown to play a role in PI3K signaling and
Akt activation [29]. In glioblastoma cells, knockdown of
galectin-1 impairs the ability of insulin-like growth factor
(IGF1) stimulation to elevate cellular PIP3 levels (Perry et
al.,2010, AACR 101
st annual meeting abstract 301). Our data
indicate that MTDH-mediated up-regulation of galectin-1 and
CALB1 may be the mechanism by which MTDH stimulates an
increase in PIP3 levels, thereby activating the PI3K/AKT/
mTOR pathway. This pathway plays an important role in
endometrial carcinogenesis, either by the mutation of PTEN or
by other mechanisms, constitutive activation is the rule. Our
identification of the over-expression of MTDH leading to
increased PIP3 levels provides yet another potential explanation
for the high activity of PI3K and AKT frequently found in
endometrial cancers.
Inhibition of MTDH was shown to increase cell death induced
by LBH589 and TRAIL combination treatment (Figure 4).
TRAIL can induce extrinsic apoptosis via directly binding with
death receptors. However, while TRAIL can selectively induce
apoptosis in endometrial cancer cells, it cannot induce apoptosis
in normal endometrial tissues at the same concentration.
Furthermore, the concentration of TRAIL (200 ng/ml) necessary
to induce apoptosis in endometrial cancer cells is much higher
than that previously used for cells from other solid tumors (e.g.
25–50 ng/ml in pancreatic cancer) [13,30]. This indicates
potential baseline resistance to TRAIL in endometrial cancer
which could be linked to high MTDH expression. To overcome
resistance, several chemotherapeutic agents or targeted inhibitors
that have been reported to increase sensitivity to TRAIL-induced
apoptosis have been used in combinatorial regimens [12]. Here
we demonstrate that the HDAC inhibitor LBH589 can increase
Figure 4. MTDH knockdown increases cell death induction by the HDAC inhibitor LBH589 alone or in combination with TRAIL. (A)
Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined
by the WST-1 method. (B) Cell death resulting from different concentrations of TRAIL (5 to 50 ng/ml) alone or in combination with 5 nM LBH589 was
analyzed in control or MTDH knockdown Hec50co cells.
doi:10.1371/journal.pone.0020920.g004
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cell death in endometrial cancer cells. Knockdown of MTDH can
further stimulate caspase-8 cleavage induced by LBH589,
TRAIL, or the combination of the two. An increase in XIAP
post-translation modification, a reduction in total XIAP, and
induction of the pro-apoptosis gene Bim were observed in cells
treated with the LBH589 alone. Loss of Bid was observed in
MTDH knockdown cells after LBH589 and TRAIL combination
treatment, which is likely due to Bid activation via cleavage. The
finding of decreased Bim with the same treatment was somewhat
unexpected. However, our data in Figure 3 suggest that MTDH
knockdown negatively regulates the Akt pathway, which may
initially result in elevated expression of Bim. As cells progress
through apoptosis, less stable proteins may be subject to
degradation. Since MTDH knockdown cells have accelerated
cell death in response to the combination treatment (Figure 4), it
is possible that the decrease in Bim is a reflection of rapid protein
turnover.
In response to LBH589 treatment alone or with TRAIL, the
two principal effects of MTDH knockdown on cell cycle were a
decrease in the percentage of cells in S and a concomitant
increase in the percent of cells inG 2 / M ,w h e r et h ec e l l sa p p e a r
to be arrested. At the cellular level, however, knockdown
MTDH alone in the absence of therapy did not affect the
Figure 5. Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control,
20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis
related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.
doi:10.1371/journal.pone.0020920.g005
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example, LBH589 significantly enhanced histone H3 acetylation
on lysine 9 (Figure 6B) which may permit the transcriptional
activation of the p21 gene [31]. However, H3 modification was
not affected by shRNA knockdown of MTDH. Proteasome-
mediated degradation of Aurora A, Aurora B and c-FLIP was
reported to be responsible for the increase in sensitivity to
TRAIL by HDAC inhibitor treatment in some cancer cells
[15,32]. However, no significant changes in Aurora A and B or
c-FLIP levels were observed in endometrial cancer cells treated
with LBH589 in our studies.
This is the first report of MTDH’s impact on resistance in
targeted therapy for endometrial cancer. For these studies, we
chose the combination of LBH589 and TRAIL because of the
impact of these agents on proapoptotic pathways. We demon-
strate herein that knockdown of MTDH sensitizes cells to
programmed cell death though a mechanism that involves
inhibition of PDK1 and Akt phosphorylation, increase in Bim,
and reduction in XIAP. Therefore, we can target MTDH to
enhance sensitivity to not only chemotherapy but also targeted
agents that work through programmed cell death. These data
provide compelling evidence that, by downregulating MTDH in
Figure 6. Cell cycle accumulation at G2/M in MTDH knockdown Hec50co cells at 24 hours after LBH589 or LBH589 and TRAIL
treatment. (A) Cell cycle profiles were determined in control or MTDH knockdown Hec50co cells at 24 hours after treatment with 20 nM LBH589,
25 ng/ml TRAIL, or LBH589 and TRAIL in combination. The percentage of cells in the G1, S and G2/M phases were determined. (B) The change in
Aurora A, Aurora B, p21, histone H3 acetylation at lysine 9, histone H3 phosphorylation at serine 10 and total histone H3 was assessed by Western
blotting following 24 hours of treatment with the indicated reagents. Total histone H3 was used as a loading control. (C) A model for the elucidated
mechanism by which knockdown of MTDH increases cell death by TRAIL and the HDAC inhibitor LBH589. MTDH knockdown decreases
phosphorylation of PDK1 and its substrate AKT, which results in increased expression of the proapoptotic protein Bim. XIAP expression is
downregulated in response to combined LBH589 and TRAIL treatment, thereby releasing the XIAP mediated inhibition of caspase-3 and -8 activation.
Collectively, the regulation of these pathways promotes apoptotic cell death.
doi:10.1371/journal.pone.0020920.g006
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and response to therapy.
Materials and Methods
Ethics Statement
Normal endometrial tissues and endometrial tissues from
endometrial cancers were collected with the consent of patients
under the University of Iowa Institutional Review Boards
approved protocol. We obtained informed written consent from
all participants involved in this study.
Cell Lines and Cell Culture
Human endometrial cancer cell lines Hec50co, RL95, AN3CA,
ECC1, Ishikawa H, and KLE were maintained as described
previously [33]. Cells were cultured in DMEM medium
containing 10% fetal bovine serum and 1% penicillin/streptomy-
cin (all from Gibco BRL, Carlsbad, CA) at 37uC in a humidified
atmosphere of 5% CO2 and 95% air. To generate an MTDH
knockdown model, Hec50co cells were transfected with MTDH sh
RNA or control non-silencing shRNA constructs per the
manufacturer’s instructions (ORIGENE, Rockville, MD). Individ-
ual cell clones resistant to puromycin were expanded and
subjected to screening for MTDH expression by Western blotting.
Endometrial Tissues and Tissue Arrays
Normal endometrial tissues and endometrial tissues from
endometrial cancers were collected from the University of Iowa
Hospitals and Clinics. The endometrial disease spectrum (endo-
metrial cancer progression) tissue array (UT 801) was purchased
from US Biomax, Inc. (Rockville, MD).
Reagents, Antibodies and Western blotting
Human recombinant TRAIL (TNF-related Apoptosis inducing
ligand) was purchased from R&D Systems, Inc. (Minneapolis,
MN). LBH589 was purchased from Selleck (Houston, TX). The
following antibodies were used: anti-MTDH and anti-b-actin
antibodies were from Sigma (St Louis, MO, USA); and anti-
cleaved caspase-3, caspase-8, DR4, DR5, Bim, Bid, FLIP, XIAP,
p21, PARP-1 p-AKT S473, p-AKT T308, PDK1, p-PDK1 S204,
histone 3, p-histone 3 serine10 and histone 3 lysine 9 acetylation
antibodies were from Cell Signaling Technology Inc. (Danvers,
MA). Whole-cell protein lysates were prepared and analyzed by
Western blotting as previously described [34].
Expression Array and RT-qPCR Analysis
Total RNA was isolated from MTDH knockdown and control
endometrial cancer cell lines (in biological triplicates for control
and MTDH knockdown cells) using the mirVana miRNA Isolation
Kit (Ambion, Austin, TX), and cDNA was generated using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Carlsbad, CA). A human gene array 1.0 ST (Affymetrix,
Santa Clara, CA) was interrogated using the biological triplicates
in the DNA Core Facility at the University of Iowa, and Partek
Genomics Suite (Partek Inc, St. Louis, MO) software was used to
generate gene expression values. All data is MIAME compliant
and the raw data has been deposited in a MIAME complaint
database GEO, as detail on the website http://www.ncbi.nlm.nih.
gov/projects/geo/query/acc.cgi?acc=GSE26134. The accession
number for Hec50co cells is GSE26134 and for Ishikawa H cells is
GSE27828. Several MTDH downstream genes were randomly
chosen to validate the microarray data using TaqMan primers and
probes (Applied Biosystems, Carlsbad, CA) for quantitative RT-
PCR analysis. Experiments were performed using biological
triplicates.
Cell Survival Assays
Cells were seeded in 96-well cell culture plates and treated the
next day with the agents as indicated. The number of viable cells
was determined using the WST-1 assay (Clontech Laboratories
Inc.), as previously described [35].
Cell Cycle Analysis
DNA content analysis by flow cytometry has been described
previously [36,37].
Supporting Information
Table S1 mRNAs that are more than two fold increased
in control shRNA expressed cells compared with MTDH
shRNA expressed Hec50co cells.
(TIF)
Table S2 mRNAs that are more than two fold decreased
in control shRNA expressed cells compared with MTDH
shRNA expressed Hec50co cells.
(TIF)
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